Accès ouvert
2026
article
OpenAlex
Shaimaa M. Aboukhatwa, Carolina Q. Sacramento, Kimberly M. Morsheimer, Christian A. Zelinski et autres
In the face of emerging outbreaks, high mortality rates, and limited treatment options, Ebola virus (EBOV) disease poses a global public health threat, underscoring the need for effective therapies. The unique and critical role that EBOV glycoprotein (GP) plays in the viral …
Égypte, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Fan Bu, Gang Ye, Kimberly M. Morsheimer, Alise Mendoza et autres
The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Malaika D. Argade, Jazmin Galván Achi, Ryan Bott, Kimberly M. Morsheimer et autres
Ebola and Marburg (EBOV and MARV) filoviral infections lead to fatal hemorrhagic fevers and have caused over 30 outbreaks in the last 50 years. Currently, there are no FDA-approved small molecule therapeutics for effectively treating filoviral diseases. To address this unmet medical …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
D. Durante, Ryan Bott, Laura Cooper, Callum D. Owen et autres
Since the largest and most fatal Ebola virus epidemic during 2014-2016, there have been several consecutive filoviral outbreaks in recent years, including those in 2021, 2022, and 2023. Ongoing outbreak prevalence and limited FDA-approved filoviral therapeutics emphasize the need for novel small …
us
(code pays fourni par la source)